Giorgio Inghirami

List of Publications by Year in Descending Order

168 papers	7,932 citations	46 h-index	87 g-index
177 ext. papers	9,920 ext. citations	8.4 avg, IF	5.57 L-index

#	Paper	IF	Citations
168	Specification of fetal liver endothelial progenitors to functional zonated adult sinusoids requires c-Maf induction.. *Cell Stem Cell*, **2022**,	18	2
167	Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.. *Frontiers in Immunology*, **2021**, 12, 809937	8.4	4
166	Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. *Blood*, **2021**,	2.2	4
165	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. *Blood*, **2021**,	2.2	5
164	Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution. *Blood*, **2021**, 138, 1323-1323	2.2	
163	Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. *Blood*, **2021**, 138, 2406-2406	2.2	
162	Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens. *Blood*, **2021**, 138, 865-865	2.2	
161	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. *Blood*, **2021**, 138, 1326-1326	2.2	0
160	HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?. *Blood*, **2021**, 138, 1377-1377	2.2	
159	High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study. *Blood*, **2021**, 138, 138-138	2.2	0
158	FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma. *Blood*, **2021**, 138, 30-30	2.2	
157	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. *Blood*, **2021**, 138, 704-704	2.2	
156	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. *Life Science Alliance*, **2021**, 4,	5.8	25
155	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. *Blood*, **2021**, 138, 213-220	2.2	7
154	Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. *Frontiers in Oncology*, **2021**, 11, 643620	5.3	
153	In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. *Current Protocols*, **2021**, 1, e96		
152	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5

151	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. *Haematologica*, **2021**, 106, 1693-1704	6.6	11
150	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. *Blood*, **2021**, 137, 788-800	2.2	6
149	Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. *European Journal of Cancer*, **2021**, 144, 17-30	7.5	1
148	induces NF-B signaling-driven peripheral T cell lymphoma. *Nature Cancer*, **2021**, 2, 98-113	15.4	5
147	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. *Cancer Discovery*, **2021**, 11, 1468-1489	24.4	27
146	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. *Frontiers in Oncology*, **2021**, 11, 701318	5.3	1
145	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. *ELife*, **2021**, 10,	8.9	1
144	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. *Cancer Research*, **2021**, 81, 5202-5216	10.1	3
143	PKC Inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. *Molecular Cell*, **2021**, 81, 4509-4526.e10	17.6	3
142	The DNA-helicase HELLS drives ALK ALCL proliferation by the transcriptional control of a cytokinesis-related program. *Cell Death and Disease*, **2021**, 12, 130	9.8	5
141	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. *Nature Medicine*, **2020**, 26, 1114-1124	50.5	63
140	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. *Haematologica*, **2020**, 105, 2432-2439	6.6	12
139	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. *Cancers*, **2020**, 12,	6.6	3
138	Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. *Nature Genetics*, **2020**, 52, 388-400	36.3	46
137	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. *Leukemia*, **2020**, 34, 2964-2980	10.7	6
136	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. *Modern Pathology*, **2020**, 33, 1380-1388	9.8	4
135	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. *Cancer Discovery*, **2020**, 10, 440-459	24.4	54
134	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. *Cell Reports*, **2020**, 30, 755-770.e6	10.6	30

133	Peripheral T cell lymphomas: from the bench to the clinic. *Nature Reviews Cancer*, **2020**, 20, 323-342	31.3	29
132	XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. *Blood*, **2020**, 136, 18-18	2.2	
131	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. *Blood Advances*, **2020**, 4, 4640-4647	7.8	20
130	519. Immune responses and COVID-19 severity. *Open Forum Infectious Diseases*, **2020**, 7, S325-S325	1	
129	Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. *Cancers*, **2020**, 12,	6.6	8
128	Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. *ELife*, **2020**, 9,	8.9	3
127	Cell cycLe inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, TPS606-TPS606	2.2	0
126	Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression **2020**,		7
125	Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *American Journal of Pathology*, **2020**, 190, 2-10	5.8	22
124	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. *Scientific Reports*, **2020**, 10, 13094	4.9	1
123	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. *Modern Pathology*, **2020**, 33, 179-187	9.8	11
122	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. *Science Translational Medicine*, **2019**, 11,	17.5	37
121	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. *Frontiers in Genetics*, **2019**, 10, 780	4.5	2
120	The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3. *Cancer Research*, **2019**, 79, 3076-3087	10.1	20
119	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. *Blood*, **2019**, 133, 1201-1204	2.2	35
118	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. *Leukemia and Lymphoma*, **2019**, 60, 1626-1631	1.9	16
117	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2019**, 60, 2838-2840	1.9	16
116	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. *American Journal of Hematology*, **2019**, 94, 628-634	7.1	7

115	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. *Leukemia*, **2019**, 33, 696-709	10.7	25
114	Repurposing dasatinib for diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 16981-16986	11.5	8
113	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. *Blood*, **2019**, 134, 4019-4019	2.2	11
112	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. *Blood*, **2019**, 134, 656-656	2.2	5
111	Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2019**, 134, 2776-2776	2.2	0
110	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. *Blood*, **2019**, 134, 173-173	2.2	
109	Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. *Blood*, **2019**, 134, 2770-2770	2.2	
108	The DNA Helicase Hells Is a New Unconventional Player in ALK- Anaplastic Large Cell Lymphoma Biology. *Blood*, **2019**, 134, 1477-1477	2.2	
107	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. *Blood*, **2019**, 133, 1664-1676	2.2	87
106	Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. *Nature* , **2019**, 567, 118-122	50.4	130
105	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. *Nature Immunology*, **2019**, 20, 86-96	19.1	39
104	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. *Human Pathology*, **2018**, 75, 167-178	3.7	9
103	Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. *British Journal of Haematology*, **2018**, 181, 642-652	4.5	31
102	Pathogenesis of Peripheral T Cell Lymphoma. *Annual Review of Pathology: Mechanisms of Disease*, **2018**, 13, 293-320	34	20
101	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. *Nature Communications*, **2018**, 9, 222	17.4	34
100	Are we ready to take full advantage of patient-derived tumor xenograft models?. *Hematological Oncology*, **2018**, 36, 24-27	1.3	1
99	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. *OncoImmunology*, **2018**, 7, e1341032	7.2	9
98	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. *British Journal of Haematology*, **2018**, 182, 453-456	4.5	3

97	Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. *Applied Immunohistochemistry and Molecular Morphology*, **2018**, 26, 383-387	1.9	28
96	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. *Cancers*, **2018**, 10,	6.6	14
95	Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. *Journal of Hematology and Oncology*, **2018**, 11, 105	22.4	18
94	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. *Blood*, **2018**, 132, 2026-2039	2.2	31
93	Patient derived organoids to model rare prostate cancer phenotypes. *Nature Communications*, **2018** , 9, 2404	17.4	149
92	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. *Journal of Clinical Investigation*, **2018**, 128, 4397-4412	15.9	33
91	Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas. *Blood*, **2018**, 132, 2922-2922	2.2	9
90	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. *Blood*, **2018**, 132, 1702-1702	2.2	3
89	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. *Blood*, **2018**, 132, 922-922	2.2	2
88	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials. *Blood*, **2018**, 132, 2962-2962	2.2	1
87	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. *Blood*, **2018**, 132, 1640-1640	2.2	
86	A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms. *Blood*, **2018**, 132, 4285-4285	2.2	
85	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. *Blood*, **2018**, 132, 2854-2854	2.2	
84	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. *Cancer Discovery*, **2018**, 8, 1632-1653	24.4	77
83	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. *Molecular Therapy - Nucleic Acids*, **2018**, 13, 334-346	10.7	31
82	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. *Nature Communications*, **2018**, 9, 2024	17.4	54
81	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 764-769	11.5	67
80	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. *Nature Communications*, **2017**, 8, 14290	17.4	58

79	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. *Experimental and Molecular Pathology*, **2017**, 102, 276-279	4.4	11
78	Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. *European Journal of Cardio-thoracic Surgery*, **2017**, 51, 680-688	3	10
77	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nature Communications*, **2017**, 8, 15618	17.4	770
76	Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. *Cancer Cell*, **2017**, 31, 110-126	24.3	76
75	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. *Cancer Research*, **2017**, 77, e62-e66	10.1	65
74	Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. *Scientific Reports*, **2017**, 7, 11301	4.9	18
73	The heterogeneous landscape of ALK negative ALCL. *Oncotarget*, **2017**, 8, 18525-18536	3.3	22
72	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. *Blood*, **2017**, 130, 645-645	2.2	
71	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. *Blood Advances*, **2016**, 1, 47-61	7.8	33
70	The genetics of nodal marginal zone lymphoma. *Blood*, **2016**, 128, 1362-73	2.2	88
69	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. *Blood*, **2016**, 127, 221-32	2.2	65
68	A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. *Blood*, **2016**, 128, 150-150	2.2	9
67	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. *Blood*, **2016**, 128, 4096-4096	2.2	1
66	Novel Long Non Coding RNA Blackmamba Is Associated to ALK- anaplastic Large Cell Lymphoma. *Blood*, **2016**, 128, 461-461	2.2	1
65	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. *Oncotarget*, **2016**, 7, 79637-79653	3.3	18
64	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. *Oncotarget*, **2016**, 7, 84675-84687	3.3	31
63	Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. *Oncotarget*, **2016**, 7, 25064-86	3.3	9
62	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. *Oncotarget*, **2016**, 7, 41913-41928	3.3	14

61	The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy. *Blood*, **2016**, 128, 279-279	2.2	
60	VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. *Blood*, **2016**, 128, 2741-2741	2.2	
59	The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. *PLoS ONE*, **2016**, 11, e0145100	3.7	36
58	Transposable elements: The enemies within. *Experimental Hematology*, **2016**, 44, 913-6	3.1	1
57	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. *Cancer Cell*, **2016**, 29, 574-586	24.3	154
56	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. *Blood*, **2016**, 127, 858-68	2.2	54
55	Stromal contribution to the colorectal cancer transcriptome. *Nature Genetics*, **2015**, 47, 312-9	36.3	407
54	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. *Clinical Cancer Research*, **2015**, 21, 1628-38	12.9	188
53	Anaplastic lymphoma kinase inhibitors. *Current Opinion in Pharmacology*, **2015**, 23, 39-44	5.1	14
52	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. *Cancer Cell*, **2015**, 27, 516-32	24.3	283
51	Integrin □3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. *Blood*, **2015**, 125, 841-51	2.2	61
50	Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition. *Human Gene Therapy*, **2015**, 26, 220-31	4.8	13
49	Epigenomic evolution in diffuse large B-cell lymphomas. *Nature Communications*, **2015**, 6, 6921	17.4	81
48	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. *Cancer Immunology Research*, **2015**, 3, 1333-1343	12.5	25
47	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. *Journal of Molecular Diagnostics*, **2015**, 17, 652-60	5.1	92
46	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. *Nature Cell Biology*, **2015**, 17, 81-94	23.4	81
45	Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. *Immunological Reviews*, **2015**, 263, 124-59	11.3	25
44	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. *Blood*, **2015**, 125, 111-23	2.2	117

43	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. *Blood*, **2015**, 125, 1061-72	2.2	206
42	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. *Blood*, **2015**, 126, 5486-5486	2.2	7
41	Anaplastic lymphoma kinase: activating mechanisms and signaling pathways. *Frontiers in Bioscience - Scholar*, **2015**, 7, 283-305	2.4	1
40	JAK-STAT in lymphoproliferative disorders. *Oncoscience*, **2015**, 2, 737-8	0.8	1
39	Assessment of T-Cell Receptor Repertoire and Clonal Expansion in Peripheral T-Cell Lymphoma Using RNA-Seq Data. *Blood*, **2015**, 126, 1451-1451	2.2	
38	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. *Cellular and Molecular Bioengineering*, **2014**, 7, 394-408	3.9	29
37	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 730-7	21.7	135
36	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood*, **2014**, 123, 1293-6	2.2	255
35	Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. *BMC Systems Biology*, **2014**, 8, 97	3.5	47
34	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. *Blood*, **2014**, 124, 1692-1692	2.2	2
33	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. *Blood*, **2014**, 124, 4417-4417	2.2	7
32	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. *Blood*, **2014**, 124, 705-705	2.2	7
31	Integrin ☒3 Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target. *Blood*, **2014**, 124, 510-510	2.2	
30	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. *Blood*, **2014**, 124, 1679-1679	2.2	
29	Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. *Blood*, **2014**, 124, 781-781	2.2	
28	Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism. *Blood*, **2014**, 124, 3316-3316	2.2	
27	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. *Blood*, **2013**, 122, 2683-93	2.2	75
26	MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. *Blood*, **2013**, 122, 2083-92	2.2	69

25	Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. *Journal of Clinical Oncology*, **2013**, 31, 3019-25	2.2	102
24	Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations. *Blood*, **2013**, 122, 3070-3070	2.2	
23	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. *Blood*, **2012**, 120, 1274-81	2.2	80
22	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. *Nature Medicine*, **2012**, 18, 1699-704	50.5	85
21	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. *Journal of Experimental Medicine*, **2012**, 209, 1537-51	16.6	289
20	CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. *Molecular Cancer Therapeutics*, **2012**, 11, 670-9	6.1	60
19	The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. *Blood*, **2012**, 120, 1657-1657	2.2	3
18	The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). *Blood*, **2012**, 120, 4872-4872	2.2	2
17	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. *Blood*, **2012**, 120, 2657-2657	2.2	
16	The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 1778-1778	2.2	
15	Anaplastic large-cell lymphoma. *Seminars in Diagnostic Pathology*, **2011**, 28, 190-201	4.3	30
14	Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *Journal of Clinical Oncology*, **2010**, 28, 1583-90	2.2	129
13	NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. *Cancer Research*, **2009**, 69, 8611-9	10.1	73
12	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. *Nature Medicine*, **2008**, 14, 676-80	50.5	93
11	The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nature Reviews Cancer*, **2008**, 8, 11-23	31.3	673
10	The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. *Cancer Research*, **2008**, 68, 8899-907	10.1	47
9	The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. *Cancer Research*, **2007**, 67, 4278-86	10.1	75
8	STAT3: a multifaceted oncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 10151-10152	11.5	80

7	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. *Nature Medicine*, **2005**, 11, 623-9	50.5	359
6	New and old functions of STAT3: a pivotal target for individualized treatment of cancer. *Cell Cycle*, **2005**, 4, 1131-3	4.7	107
5	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. *Oncogene*, **2002**, 21, 1038-47	9.2	311
4	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. *British Journal of Haematology*, **2000**, 111, 263-271	4.5	1
3	Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. *British Journal of Haematology*, **1999**, 107, 106-13	4.5	36
2	N- and K-ras oncogenes in plasma cell dyscrasias. *Leukemia and Lymphoma*, **1994**, 15, 17-20	1.9	23
1	Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment		1